Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression
- PMID: 20340170
- PMCID: PMC2888922
- DOI: 10.1002/syn.20770
Dopaminergic regulation of dopamine D3 and D3nf receptor mRNA expression
Abstract
Dopamine D3 receptors have the highest dopamine affinity of all dopamine receptors, and may thereby regulate dopamine signaling mediated by volume transmission. Changes in D3 receptor isoform expression may alter D3 receptor function, however, little is known regarding coordination of D3 isoform expression in response to perturbations in dopaminergic stimulation. To determine the effects of dopamine receptor stimulation and blockade on D3 receptor alternative splicing, we determined D3 and D3nf isoform mRNA expression following treatment with the D3 receptor antagonist NGB 2904, and the indirect dopamine agonist amphetamine. Expression of tyrosine hydroxylase (TH) mRNA, the rate-limiting enzyme in dopamine synthesis, was also determined. The D3/D3nf mRNA expression ratio was increased in ventral striatum, prefrontal cortex, and hippocampus 6 h following D3 antagonist NGB 2904 treatment, and remained persistently elevated at 24 h in hippocampus and substantia nigra/ventral tegmentum. D3 mRNA decreased 65% and D3nf mRNA expression decreased 71% in prefrontal cortex 24 h following amphetamine treatment, however, these changes did not reach statistical significance. TH mRNA expression was unaffected by D3 antagonist NGB 2904, but was elevated by amphetamine in ventral striatum, hippocampus, and prefrontal cortex. These findings provide evidence for an adaptive response to altered D3 receptor stimulation involving changes in D3 receptor alternative splicing. Additionally, these data suggest D3 autoreceptor regulation of dopamine synthesis does not involve regulation of TH mRNA expression. Finally, the observation of regulated TH mRNA expression in dopamine terminal fields provides experimental support for the model of local control of mRNA expression in adaptation to synaptic activity.
Figures







Similar articles
-
C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.Neuroscience. 2006 Nov 17;143(1):141-53. doi: 10.1016/j.neuroscience.2006.07.015. Epub 2006 Aug 28. Neuroscience. 2006. PMID: 16938406 Free PMC article.
-
Relative expression of D3 dopamine receptor and alternative splice variant D3nf mRNA in high and low responders to novelty.Brain Res Bull. 2006 Oct 16;70(4-6):296-303. doi: 10.1016/j.brainresbull.2006.06.010. Epub 2006 Jul 13. Brain Res Bull. 2006. PMID: 17027765 Free PMC article.
-
The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion.Pharmacol Biochem Behav. 2007 Apr;86(4):718-26. doi: 10.1016/j.pbb.2007.02.019. Epub 2007 Mar 6. Pharmacol Biochem Behav. 2007. PMID: 17408730
-
Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function.Neuropsychopharmacology. 2006 Nov;31(11):2368-75. doi: 10.1038/sj.npp.1301163. Epub 2006 Jul 19. Neuropsychopharmacology. 2006. PMID: 16855531 Free PMC article. Review.
-
The potential role of dopamine D₃ receptor neurotransmission in cognition.Eur Neuropsychopharmacol. 2013 Aug;23(8):799-813. doi: 10.1016/j.euroneuro.2013.05.006. Epub 2013 Jun 20. Eur Neuropsychopharmacol. 2013. PMID: 23791072 Free PMC article. Review.
Cited by
-
Neurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures.ISRN Neurol. 2013 May 7;2013:875834. doi: 10.1155/2013/875834. Print 2013. ISRN Neurol. 2013. PMID: 23738145 Free PMC article.
-
Modulation of D3R Splicing, Signaling, and Expression by D1R through PKA→PTB Phosphorylation.Biomedicines. 2024 Jan 17;12(1):206. doi: 10.3390/biomedicines12010206. Biomedicines. 2024. PMID: 38255311 Free PMC article.
-
Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.Biomolecules. 2022 Feb 1;12(2):243. doi: 10.3390/biom12020243. Biomolecules. 2022. PMID: 35204744 Free PMC article. Review.
-
The influence of dopamine autoreceptors on temperament and addiction risk.Neurosci Biobehav Rev. 2023 Dec;155:105456. doi: 10.1016/j.neubiorev.2023.105456. Epub 2023 Nov 3. Neurosci Biobehav Rev. 2023. PMID: 37926241 Free PMC article. Review.
-
Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia.Biomedicines. 2021 Mar 19;9(3):314. doi: 10.3390/biomedicines9030314. Biomedicines. 2021. PMID: 33808538 Free PMC article. Review.
References
-
- Elmhurst JL, Xie Z, O’Dowd BF, George SR. The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. Brain Res Mol Brain Res. 2000;80:63–74. - PubMed
-
- Fedele E, Fontana G, Munari C, Cossu M, Raiteri M. Native human neocortex release-regulating dopamine D2 type autoreceptors are dopamine D2 subtype. Eur J Neurosci. 1999;11:2351–2358. - PubMed
-
- Fishburn CS, Belleli D, David C, Carmon S, Fuchs S. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J Biol Chem. 1993;268:5872–5878. - PubMed
-
- Goldstein M. Long- and short-term regulation of tyrosine hydroxylase. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press; 1995. pp. 189–195.
-
- Gregory H, Taylor CL, Hopkins CR. Luteinizing hormone release from dissociated pituitary cells by dimerization of occupied LHRH receptors. Nature. 1982;300:269–271. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources